Post-earnings recap
Reported
Tue, May 10, 2022
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
75%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Aurinia Pharmaceuticals reported a loss of $0.27 per share, slightly missing expectations. Despite this, the stock surged by nearly 26%, indicating strong investor interest or positive sentiment in the company's future prospects, even without detailed commentary from management.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.27 | N/A | -5.06% |
| Revenue | — | N/A | — |
No transcript is on record, and the analysis is based on numerical results only.